<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384577</url>
  </required_header>
  <id_info>
    <org_study_id>BFS-AS-40074</org_study_id>
    <secondary_id>DRKS00006542</secondary_id>
    <nct_id>NCT02384577</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment</brief_title>
  <official_title>Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp® SPIROMAX® and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to investigate patient satisfaction in the treatment of asthma
      and COPD with the new device of DuoResp® Spiromax® and patient preference. Possible
      difficulties in the use of the device under real-life conditions in clinical practice are
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study detects the instruction expense in the use of the inhaler, reasons for the choice
      of the medication, or a switch in treatment of asthma or COPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Satisfaction and Preference Questionnaire (PASAPQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Satisfaction and preference of patients treated with DuoResp® Spiromax® using PASAPQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Practicability of the device</measure>
    <time_frame>12 weeks</time_frame>
    <description>Investigation of practicability of the device for patients using checklist inhalation errors</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4034</enrollment>
  <condition>Patient Satisfaction</condition>
  <arm_group>
    <arm_group_label>Single group prospective treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide, Formoterol Fumarate Dihydrate</intervention_name>
    <arm_group_label>Single group prospective treatment</arm_group_label>
    <other_name>DuoResp® Spiromax®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult asthma or COPD-patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female adult patients with clinical diagnosis of bronchial asthma or chronic
             obstructive pulmonary disease

          -  patients on regular medication with inhaled corticosteroids and long-acting
             beta-2-agonists in fixed-dose combination

          -  patients who recently changed medication to DuoResp® Spiromax or are about to do so

          -  capacitated person with present declaration of consent

        Exclusion Criteria:

          -  diseases contraindicated in accordance with the summary of product characteristic

          -  patients who take part in interventional clinical trials parallel or during the last 4
             weeks

          -  patient shows conditions or diseases that might disturb the monitoring according to
             the physician

          -  patients with substance misuse in their case history (drugs, alcohol) or with other
             factors (e.g. serious psychiatric conditions) that limit their ability to participate
             in the study

          -  insufficient German language knowledge to understand the patient education and to
             complete the questionnaires in a correct manner

          -  patients involved in the planning and construction of the study (Teva staff and
             employees of the centres)

          -  patient is incapable of giving consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Sites</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

